36 related articles for article (PubMed ID: 8417130)
1. Natural killer (NK) cell immunodeficiency in patients with chronic myelogenous leukemia. II. Successful cloning and amplification of natural killer cells.
Fujimiya Y; Chang WC; Bakke A; Horwitz D; Pattengale PK
Cancer Immunol Immunother; 1987; 24(3):213-20. PubMed ID: 3496152
[TBL] [Abstract][Full Text] [Related]
2. Hexabromocyclododecane decreases tumor-cell-binding capacity and cell-surface protein expression of human natural killer cells.
Hinkson NC; Whalen MM
J Appl Toxicol; 2010 May; 30(4):302-9. PubMed ID: 19938002
[TBL] [Abstract][Full Text] [Related]
3. Serum supplementation modulates the effects of dibutyltin on human natural killer cell function.
Whalen MM; DeWitt JC; Luebke RW
Toxicol Sci; 2008 Aug; 104(2):312-9. PubMed ID: 18441343
[TBL] [Abstract][Full Text] [Related]
4. Pentachlorophenol decreases tumor-cell-binding capacity and cell-surface protein expression of human natural killer cells.
Hurd T; Walker J; Whalen MM
J Appl Toxicol; 2012 Aug; 32(8):627-34. PubMed ID: 22912977
[TBL] [Abstract][Full Text] [Related]
5. Differences in nature killer cell response and interference with mitochondrial DNA induced apoptosis in moxifloxacin environment.
Wang M; Wu H; Jiang W; Ren Y; Yuan X; Wang Y; Zhou J; Feng W; Wang Y; Xu T; Zhang D; Fang Y; He C; Li W
Int Immunopharmacol; 2024 May; 132():111970. PubMed ID: 38608472
[TBL] [Abstract][Full Text] [Related]
6. Effects of a series of triorganotins on ATP levels in human natural killer cells.
Holloway LN; Pannell KH; Whalen MM
Environ Toxicol Pharmacol; 2008 Jan; 25(1):43-50. PubMed ID: 19122738
[TBL] [Abstract][Full Text] [Related]
7. Interferon-alpha activates cytotoxic function but inhibits interleukin-2-mediated proliferation and tumor necrosis factor-alpha secretion by immature human natural killer cells.
Jewett A; Bonavida B
J Clin Immunol; 1995 Jan; 15(1):35-44. PubMed ID: 7759599
[TBL] [Abstract][Full Text] [Related]
8. Natural killer cell subsets: maturation, differentiation and regulation.
Bonavida B; Lebow LT; Jewett A
Nat Immun; 1993; 12(4-5):194-208. PubMed ID: 8257826
[TBL] [Abstract][Full Text] [Related]
9. Qualitative and quantitative analysis of subpopulations of cytotoxic effector cells by flow cytometry.
Bonavida B; Braquet M; Lebow LT; Jewett A
J Lipid Mediat Cell Signal; 1994 Feb; 9(1):19-25. PubMed ID: 8032712
[TBL] [Abstract][Full Text] [Related]
10. Killer cell recruitment and renewal capacity of purified cytolytic and noncytolytic human peripheral blood natural killer cell subsets.
Lebow LT; Jewett A; Bonavida B
J Immunol; 1993 Jan; 150(1):320-9. PubMed ID: 8417130
[TBL] [Abstract][Full Text] [Related]
11. Cord blood CD16+56- cells with low lytic activity are possible precursors of mature natural killer cells.
Gaddy J; Broxmeyer HE
Cell Immunol; 1997 Sep; 180(2):132-42. PubMed ID: 9341743
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of tyrosine kinase inhibition in CD69 antigen expression and lytic activity induced by rIL-2, rIL-12, and rIFN-alpha in human NK cells.
Gerosa F; Tommasi M; Benati C; Gandini G; Libonati M; Tridente G; Carra G; Trinchieri G
Cell Immunol; 1993 Sep; 150(2):382-90. PubMed ID: 8103709
[TBL] [Abstract][Full Text] [Related]
13. Prostaglandin E2-induced changes in the phenotype, morphology, and lytic activity of IL-2-activated natural killer cells.
Linnemeyer PA; Pollack SB
J Immunol; 1993 May; 150(9):3747-54. PubMed ID: 8386202
[TBL] [Abstract][Full Text] [Related]
14. Interferon-beta and recombinant IL 2 can both enhance, but by different pathways, the nonspecific cytolytic potential of T3- natural killer cell-derived clones rather than that of T3+ clones.
van de Griend RJ; Ronteltap CP; Gravekamp C; Monnikendam D; Bolhuis RL
J Immunol; 1986 Mar; 136(5):1700-7. PubMed ID: 3005399
[TBL] [Abstract][Full Text] [Related]
15. Induction of natural killer effectors from human thymus with recombinant IL-2.
Michon JM; Caligiuri MA; Hazanow SM; Levine H; Schlossman SF; Ritz J
J Immunol; 1988 May; 140(10):3660-7. PubMed ID: 3258886
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
